These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 9498772)
21. Decay-accelerating factor (DAF/CD55) is a functional active element of the LPS receptor complex. Heine H; Ulmer AJ; El-Samalouti VT; Lentschat A; Hamann L J Endotoxin Res; 2001; 7(3):227-31. PubMed ID: 11581575 [TBL] [Abstract][Full Text] [Related]
22. Echoviruses bind heparan sulfate at the cell surface. Goodfellow IG; Sioofy AB; Powell RM; Evans DJ J Virol; 2001 May; 75(10):4918-21. PubMed ID: 11312365 [TBL] [Abstract][Full Text] [Related]
23. Comparative analysis of two coxsackievirus B3 strains: putative influence of virus-receptor interactions on pathogenesis. Selinka HC; Wolde A; Pasch A; Klingel K; Schnorr JJ; Küpper JH; Lindberg AM; Kandolf R J Med Virol; 2002 Jun; 67(2):224-33. PubMed ID: 11992583 [TBL] [Abstract][Full Text] [Related]
24. Characterization of the echovirus 7 receptor: domains of CD55 critical for virus binding. Clarkson NA; Kaufman R; Lublin DM; Ward T; Pipkin PA; Minor PD; Evans DJ; Almond JW J Virol; 1995 Sep; 69(9):5497-501. PubMed ID: 7543583 [TBL] [Abstract][Full Text] [Related]
25. A single amino acid substitution controls DAF-dependent phenotype of echovirus 11 in rhabdomyosarcoma cells. Novoselov AV; Rezaykin AV; Sergeev AG; Fadeyev FA; Grigoryeva JV; Sokolova ZI Virus Res; 2012 Jun; 166(1-2):87-96. PubMed ID: 22445689 [TBL] [Abstract][Full Text] [Related]
26. Attachment of coxsackievirus B3 variants to various cell lines: mapping of phenotypic differences to capsid protein VP1. Schmidtke M; Selinka HC; Heim A; Jahn B; Tonew M; Kandolf R; Stelzner A; Zell R Virology; 2000 Sep; 275(1):77-88. PubMed ID: 11017789 [TBL] [Abstract][Full Text] [Related]
27. Cytoplasmic interactions between decay-accelerating factor and intercellular adhesion molecule-1 are not required for coxsackievirus A21 cell infection. Shafren DR; Dorahy DJ; Thorne RF; Barry RD J Gen Virol; 2000 Apr; 81(Pt 4):889-94. PubMed ID: 10725413 [TBL] [Abstract][Full Text] [Related]
28. Specificity of coxsackievirus B3 interaction with human, but not murine, decay-accelerating factor: replacement of a single residue within short consensus repeat 2 prevents virus attachment. Pan J; Zhang L; Organtini LJ; Hafenstein S; Bergelson JM J Virol; 2015 Jan; 89(2):1324-8. PubMed ID: 25392210 [TBL] [Abstract][Full Text] [Related]
29. Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor: a mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis. Mason JC; Lidington EA; Yarwood H; Lublin DM; Haskard DO Arthritis Rheum; 2001 Jan; 44(1):138-50. PubMed ID: 11212152 [TBL] [Abstract][Full Text] [Related]
30. Short consensus repeat domain 1 of decay-accelerating factor is required for enterovirus 70 binding. Karnauchow TM; Dawe S; Lublin DM; Dimock K J Virol; 1998 Nov; 72(11):9380-3. PubMed ID: 9765493 [TBL] [Abstract][Full Text] [Related]
31. CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma. Chen S; Caragine T; Cheung NK; Tomlinson S Cancer Res; 2000 Jun; 60(11):3013-8. PubMed ID: 10850450 [TBL] [Abstract][Full Text] [Related]
32. Characterization of C3dg binding to a recess formed between short consensus repeats 1 and 2 of complement receptor type 2 (CR2; CD21). Prodinger WM; Schwendinger MG; Schoch J; Köchle M; Larcher C; Dierich MP J Immunol; 1998 Nov; 161(9):4604-10. PubMed ID: 9794388 [TBL] [Abstract][Full Text] [Related]
33. Development of a recombinant CHO cell model for the investigation of CAR and DAF role during early steps of echovirus 6 infection. Renois F; Hong SS; Le Naour R; Gafa V; Talmud D; Andréoletti L; Lévêque N Virus Res; 2011 Jun; 158(1-2):46-54. PubMed ID: 21420451 [TBL] [Abstract][Full Text] [Related]
34. Interaction of decay-accelerating factor with coxsackievirus B3. Hafenstein S; Bowman VD; Chipman PR; Bator Kelly CM; Lin F; Medof ME; Rossmann MG J Virol; 2007 Dec; 81(23):12927-35. PubMed ID: 17804498 [TBL] [Abstract][Full Text] [Related]
35. Enterovirus capsid interactions with decay-accelerating factor mediate lytic cell infection. Newcombe NG; Johansson ES; Au G; Lindberg AM; Barry RD; Shafren DR J Virol; 2004 Feb; 78(3):1431-9. PubMed ID: 14722298 [TBL] [Abstract][Full Text] [Related]
36. Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Au GG; Lincz LF; Enno A; Shafren DR Br J Haematol; 2007 Apr; 137(2):133-41. PubMed ID: 17391493 [TBL] [Abstract][Full Text] [Related]
37. Decay-accelerating factor in the periovulatory rat ovary. Gieske MC; Na GY; Koo Y; Jo M; Curry TE; Ko C J Endocrinol; 2005 Aug; 186(2):303-13. PubMed ID: 16079256 [TBL] [Abstract][Full Text] [Related]